Rocket Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 69 to 74.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's unique RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating of above 80 as they begin their largest price moves. See if Rocket Pharmaceuticals stock can continue to show renewed price strength and clear that threshold.
See How IBD Helps You Make More Money In Stocks
Is Rocket Pharmaceuticals Stock A Buy?
Rocket Pharmaceuticals stock is not currently offering a proper buying opportunity. This is not the time to buy stocks during a market correction, but build a watchlist of possible emerging leaders once the market trend turns around.
The gene-editing biotech company showed 0% earnings growth in the latest quarterly report, while sales growth came in at 0%. Look for the next report on or around Nov. 8.
Rocket Pharmaceuticals stock holds the No. 167 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals and HUTCHMED (China) ADR are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
